- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 45
- States / cities
- La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
Location Directory
Clinical trials in Aurora, Colorado
This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 673–684 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Institutions in Aurora
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 23
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
- Conditions
- Peanut Allergies
- Interventions
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
- Drug
- Lead sponsor
- Mabylon AG
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
- Conditions
- Pelvic Pain, Pelvic Floor Dysfunction, Voiding Dysfunction
- Interventions
- Home Pelvic Floor Trainer
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab, Placebo
- Biological · Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- REM Behavior Disorder, Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- CND Life Sciences
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 171
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
- Conditions
- Atrial Fibrillation
- Interventions
- BAY 3670549, Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Pulmonary Disease, Transcatheter Pulmonary Valve Replacement (TPVR), Tetralogy of Fallot, Congenital Heart Disease, Pulmonary Regurgitation
- Interventions
- Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- CLN3
- Interventions
- Miglustat oral liquid formulation (250 mg/mL)
- Drug
- Lead sponsor
- Beyond Batten Disease Foundation
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Houston, Texas
- Conditions
- Cancer
- Interventions
- 4 Corners Rural Health Cancer Prevention
- Behavioral
- Lead sponsor
- Klein Buendel, Inc.
- Industry
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 1,796 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 2 more
- Conditions
- Danon Disease
- Interventions
- No intervention
- Other
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 6 more